Haosun passed US FDA inspection in 2025

Haosun passed US FDA Unannounced Inspection with Zero Deficiencies (NAI) during 28th Jul to 1st Aug 2025. 
This is our sixth successful US FDA on-site audit, demonstrating our quality management system has once again received recognition from an international pharmaceutical regulatory authority.

Products including: Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, Temozolomide, Dasatinib, Dasatinib Anhydrous, Desvenlafaxine Succinate, Neostigmine Methylsulfate, Nilotinib Hydrochloride Monohydrate